BioCentury
ARTICLE | Product Development

Big gain for Cassava on little efficacy data in Alzheimer’s

February 3, 2021 1:02 AM UTC

Cassava more than doubled its share price Tuesday on a small amount of uncontrolled data in Alzheimer’s disease and the disclosure that it will move simufilam to Phase III in the indication.

Cassava Sciences Inc. (NASDAQ:SAVA) rose $32.45 (141%) to $55.44 Tuesday, adding $830 million in market cap. The move puts the biotech’s share price back in the range it was at in 2011, before a series of four complete response letters (CRLs) from FDA ultimately caused the company to discontinue its lead pain program Remoxy ER. ...

BCIQ Company Profiles

Cassava Sciences Inc.